Literature DB >> 33211673

The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury.

Paul F Lebeau1, Hanny Wassef2, Jae Hyun Byun1, Khrystyna Platko1, Brandon Ason3, Simon Jackson3, Joshua Dobroff4, Susan Shetterly3, William G Richards5, Ali A Al-Hashimi1, Kevin Doyoon Won1, Majambu Mbikay2, Annik Prat6, An Tang7, Guillaume Paré8, Renata Pasqualini9, Nabil G Seidah6, Wadih Arap10, Michel Chrétien2, Richard C Austin1.   

Abstract

Individuals harboring the loss-of-function (LOF) proprotein convertase subtilisin/kexin type 9 Gln152His variation (PCSK9Q152H) have low circulating low-density lipoprotein cholesterol levels and are therefore protected against cardiovascular disease (CVD). This uncleavable form of proPCSK9, however, is retained in the endoplasmic reticulum (ER) of liver hepatocytes, where it would be expected to contribute to ER storage disease (ERSD), a heritable condition known to cause systemic ER stress and liver injury. Here, we examined liver function in members of several French-Canadian families known to carry the PCSK9Q152H variation. We report that PCSK9Q152H carriers exhibited marked hypocholesterolemia and normal liver function despite their lifelong state of ER PCSK9 retention. Mechanistically, hepatic overexpression of PCSK9Q152H using adeno-associated viruses in male mice greatly increased the stability of key ER stress-response chaperones in liver hepatocytes and unexpectedly protected against ER stress and liver injury rather than inducing them. Our findings show that ER retention of PCSK9 not only reduced CVD risk in patients but may also protect against ERSD and other ER stress-driven conditions of the liver. In summary, we have uncovered a cochaperone function for PCSK9Q152H that explains its hepatoprotective effects and generated a translational mouse model for further mechanistic insights into this clinically relevant LOF PCSK9 variant.

Entities:  

Keywords:  Atherosclerosis; Cell stress; Cholesterol; Hepatology; Vascular Biology

Year:  2021        PMID: 33211673      PMCID: PMC7810474          DOI: 10.1172/JCI128650

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

Review 1.  Endoplasmic reticulum storage diseases.

Authors:  Jonas Rutishauser; Martin Spiess
Journal:  Swiss Med Wkly       Date:  2002-05-04       Impact factor: 2.193

2.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

Review 3.  Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.

Authors:  Nabil G Seidah; Annik Prat; Angela Pirillo; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

4.  Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions.

Authors:  Elizabeth D Crane; Ali A Al-Hashimi; Jack Chen; Edward G Lynn; Kevin Doyoon Won; Šárka Lhoták; Magda Naeim; Khrystyna Platko; Paul Lebeau; Jae Hyun Byun; Bobby Shayegan; Joan C Krepinsky; Katey J Rayner; Serena Marchiò; Renata Pasqualini; Wadih Arap; Richard C Austin
Journal:  JCI Insight       Date:  2018-12-20

5.  Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained.

Authors:  Paul Lebeau; Khrystyna Platko; Ali A Al-Hashimi; Jae Hyun Byun; Šárka Lhoták; Nicholas Holzapfel; Gabriel Gyulay; Suleiman A Igdoura; David R Cool; Bernardo Trigatti; Nabil G Seidah; Richard C Austin
Journal:  J Biol Chem       Date:  2018-03-28       Impact factor: 5.157

6.  Pharmacologic inhibition of S1P attenuates ATF6 expression, causes ER stress and contributes to apoptotic cell death.

Authors:  Paul Lebeau; Jae Hyun Byun; Tamana Yousof; Richard C Austin
Journal:  Toxicol Appl Pharmacol       Date:  2018-04-22       Impact factor: 4.219

7.  Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP.

Authors:  Yi Zhang; Ren Liu; Min Ni; Parkash Gill; Amy S Lee
Journal:  J Biol Chem       Date:  2010-03-05       Impact factor: 5.157

8.  Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Authors:  Ahmed Zaid; Anna Roubtsova; Rachid Essalmani; Jadwiga Marcinkiewicz; Ann Chamberland; Josée Hamelin; Michel Tremblay; Hélène Jacques; Weijun Jin; Jean Davignon; Nabil G Seidah; Annik Prat
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

9.  Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice.

Authors:  Marc S Sabatine; James A Underberg; Michael Koren; Seth J Baum
Journal:  Postgrad Med       Date:  2016-07-14       Impact factor: 3.840

Review 10.  PCSK9 inhibitors in the prevention of cardiovascular disease.

Authors:  James Latimer; Jonathan A Batty; R Dermot G Neely; Vijay Kunadian
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

View more
  8 in total

1.  Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity.

Authors:  Jae Hyun Byun; Paul F Lebeau; Khrystyna Platko; Rachel E Carlisle; Mahi Faiyaz; Jack Chen; Melissa E MacDonald; Yumna Makda; Tamana Yousof; Edward G Lynn; Jeffrey G Dickhout; Joan C Krepinsky; Fiona Weaver; Suleiman A Igdoura; Nabil G Seidah; Richard C Austin
Journal:  Kidney360       Date:  2022-04-27

2.  DRP1: a novel regulator of PCSK9 secretion and degradation.

Authors:  Sean A Burnap; Manuel Mayr
Journal:  Cardiovasc Res       Date:  2021-09-28       Impact factor: 13.081

Review 3.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

4.  Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes.

Authors:  Małgorzata Waluś-Miarka; Maria Kapusta; Przemysław Miarka; Ewa Kawalec; Barbara Idzior-Waluś
Journal:  Cardiovasc Ther       Date:  2021-12-21       Impact factor: 3.023

Review 5.  Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.

Authors:  Thomas Grewal; Christa Buechler
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

6.  Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol.

Authors:  George N Ioannou; Sum P Lee; Peter S Linsley; Vivian Gersuk; Matthew M Yeh; Yen-Ying Chen; Yi-Jen Peng; Moumita Dutta; Gabby Mascarinas; Bruk Molla; Julia Yue Cui; Christopher Savard
Journal:  Hepatol Commun       Date:  2021-11-24

Review 7.  Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond.

Authors:  Nabil G Seidah; Damien Garçon
Journal:  Curr Atheroscler Rep       Date:  2022-07-29       Impact factor: 5.967

Review 8.  The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases.

Authors:  Paul F Lebeau; Khrystyna Platko; Jae Hyun Byun; Yumna Makda; Richard C Austin
Journal:  Metabolites       Date:  2022-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.